Royalty Pharma plc
RPRX
Pozycja w akcjach
#874
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Cena akcji
$61.75
Kapitalizacja rynkowa
$27.50B
Zmiana (1 dzień)
2.46%
Zmiana (1 rok)
68.58%
Kraj
US
Handel Royalty Pharma plc (RPRX)
Kategoria
Healthcare
Zyski dla Royalty Pharma plc (RPRX)
Zyski w Jun 2026 TTM: $1.35B
Według najnowszych raportów finansowych Royalty Pharma plc, obecny zysk firmy wynosi $1.35B. W roku 2024 firma osiągnęła zysk w wysokości $1.33B, spadek w porównaniu do zysku z roku 2023, który wynosił $1.70B. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Royalty Pharma plc od 2015 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $1.35B | 1.94% |
| 2025 | $1.32B | -0.50% |
| 2024 | $1.33B | -21.72% |
| 2023 | $1.70B | 638.96% |
| 2022 | $230.06M | -81.46% |
| 2021 | $1.24B | -27.07% |
| 2020 | $1.70B | -30.85% |
| 2019 | $2.46B | 62.16% |
| 2018 | $1.52B | 13.00% |
| 2017 | $1.34B | 76.29% |
| 2016 | $761.90M | 0.42% |
| 2015 | $758.71M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -98.05% |
US
|
|
| $1.21B | -10.73% |
HK
|
